Delayed Type IV Hypersensitivity

Type IV Hypersensitivity (Delayed-Type Hypersensitivity) What Is Type IV Hypersensitivity? Type IV hypersensitivity is an immune reaction that develops slowly—typically 48 to 72 hours after antigen exposure—as opposed to the rapid reactions of Types I, II, and III. This delay is why it's also called delayed-type hypersensitivity. Unlike the first three types, Type IV reactions rely entirely on T lymphocytes, not antibodies. This makes it fundamentally a cellular immune response rather than a humoral one. The key characteristic that distinguishes Type IV from other hypersensitivities is this delayed timeline and the involvement of memory T cells. When you encounter an antigen for the first time, your immune system sensitizes to it. Upon re-exposure to that same antigen, memory T cells rapidly activate and orchestrate an inflammatory response at the site of exposure. The Cellular Basis: T Cells and Antigen Presentation Type IV hypersensitivity is initiated when an antigen is presented on class II major histocompatibility complex (MHC) proteins to CD4+ T lymphocytes. This is the critical first step. CD4+ T cells recognize the antigen and become activated, leading to their differentiation into various effector subtypes, which we'll discuss shortly. During an initial sensitization event, activated CD4+ T cells develop into memory T cells specific to that antigen. These memory cells persist for years, sometimes decades. When you're re-exposed to the same antigen later, these memory cells immediately recognize it and rapidly proliferate and secrete cytokines, recruiting and activating other immune cells at the site of exposure. It's worth noting that CD8+ cytotoxic T lymphocytes may also participate in Type IV reactions (particularly in Type IVc, as we'll see), but they generally require help from CD4+ T cells to become fully activated. The Four Subtypes of Type IV Hypersensitivity The key to understanding Type IV hypersensitivity is recognizing that it's not a single reaction—it's four distinct subtypes, each with a different inflammatory signature based on which effector T cells are involved and which cytokines they produce. The subtype that develops depends on the nature of the antigen and the type of immune response it triggers. Type IVa: Th1-Macrophage-Predominant Type IVa is the classical, most common form of Type IV hypersensitivity. It occurs when CD4+ T lymphocytes differentiate into T helper 1 (Th1) cells. Th1 cells secrete two key cytokines: Interferon-gamma (IFN-γ) Tumor necrosis factor-alpha (TNF-α) These cytokines activate macrophages, making them more aggressive and better at killing pathogens and presenting antigen. In acute responses, you see a lymphocytic and macrophage infiltrate. However, in chronic Type IVa reactions, the continuous activation of macrophages leads to granuloma formation—a distinctive pathological finding where epithelioid macrophages and giant cells cluster together to wall off persistent antigens. Classic example: Tuberculosis skin test (Mantoux test). The classic presentation of chronic Type IVa hypersensitivity includes conditions like tuberculosis, leprosy, and contact dermatitis to certain chemicals. Type IVb: Th2-Eosinophil-Predominant Type IVb occurs when CD4+ T lymphocytes differentiate into T helper 2 (Th2) cells instead of Th1 cells. Th2 cells produce: Interleukin-4 (IL-4) Interleukin-5 (IL-5) Interleukin-13 (IL-13) These cytokines drive eosinophil recruitment and activation. The inflammatory infiltrate is dominated by eosinophils, making this subtype distinguishable by histology. This subtype is less common than Type IVa but occurs in certain drug reactions and parasitic infections. Type IVc: Cytotoxic T Lymphocyte-Predominant Type IVc is driven by CD8+ cytotoxic T lymphocytes (CTLs). These cells directly kill infected or aberrant cells using several mechanisms: Release of perforin, which creates pores in target cell membranes Release of granzyme B, which enters through perforin pores and triggers apoptosis Engagement of Fas-Fas ligand interactions, another apoptosis pathway This subtype causes direct cell death, particularly of keratinocytes (skin cells). You'll see epidermal necrosis on histology. Type IVc reactions are responsible for certain drug-induced reactions and severe contact dermatitis presentations. Type IVd: Th17-Neutrophil-Predominant Type IVd is driven by T helper 17 (Th17) cells, which produce interleukin-17 (IL-17). Interestingly, some older literature groups this under Th1 responses, but modern understanding recognizes Th17 as distinct. IL-17 is a potent neutrophil chemoattractant and activator. Additionally, Th17 cells secrete: CXCL8 (Interleukin-8) Granulocyte-macrophage colony-stimulating factor (GM-CSF) These cause rapid neutrophil recruitment and activation. The inflammatory infiltrate is predominantly neutrophilic. Type IVd reactions are important in certain infections and autoimmune conditions. The Pathogenesis: How Type IV Reactions Develop Understanding the pathway helps you predict clinical presentation: Initial Sensitization: Upon first exposure to an antigen, antigen-presenting cells process it and present it to naive CD4+ T cells on class II MHC. Depending on the context and nature of the antigen, the T cells differentiate into Th1, Th2, Th17, or support CD8+ responses. Memory Formation: These activated T cells develop into memory cells specific to that antigen. They remain in lymphoid tissues and the circulation. Re-exposure and Rapid Activation: When the antigen is encountered again, memory T cells immediately recognize it and become activated. They rapidly proliferate and secrete large amounts of cytokines. Recruitment and Activation of Effector Cells: The specific cytokines secreted (IFN-γ for Type IVa, IL-5 for Type IVb, granzyme for Type IVc, IL-17 for Type IVd) recruit and activate the corresponding effector cell type—macrophages, eosinophils, cytotoxic lymphocytes, or neutrophils. Local Inflammation: The effector cells cause tissue damage through various mechanisms (macrophage killing in IVa, direct cytotoxicity in IVc, enzyme release from neutrophils in IVd, etc.). Chronic Phase (in persistent exposure): If the antigen persists, chronic induration develops. In Type IVa, this manifests as granulomas. In other subtypes, ongoing tissue remodeling and fibrosis may occur. The 48-72 hour delay exists because it takes time for memory T cells to proliferate, for cytokines to accumulate, and for effector cells to be recruited and exert their effects. This is different from Type I hypersensitivity, where preformed mediators cause symptoms within minutes. Diagnosis Diagnosis of Type IV hypersensitivity relies on demonstrating the delayed cellular response, usually through skin testing. Patch Testing for Contact Dermatitis For suspected contact dermatitis (typically Type IVa), suspected allergens are applied to small patches on the skin, usually on the back. The skin is then examined at 48 and 72 hours for induration (thickening and hardening of the skin). A positive reaction shows localized redness, swelling, and sometimes vesicles at the site of the allergen. This test is both diagnostic and identifies which specific allergen is responsible. Intradermal Testing: The Tuberculin Skin Test The tuberculin skin test (TST or Mantoux test) is a classic example used for diagnosing tuberculosis exposure. Purified protein derivative (PPD) from Mycobacterium tuberculosis is injected intradermally. In sensitized individuals, induration (not just redness) measuring ≥5-15 mm (depending on risk factors) at 48-72 hours indicates TB infection. This reaction is Type IVa hypersensitivity. Histopathology Depending on the subtype, skin biopsy shows: Type IVa: Lymphocytic infiltrate with macrophages; granulomas if chronic Type IVb: Eosinophil-rich infiltrate Type IVc: Epidermal necrosis, lymphocytic infiltrate Type IVd: Neutrophilic infiltrate Management Management of Type IV hypersensitivity focuses on reducing T cell-mediated inflammation and, when possible, avoiding the triggering antigen. Corticosteroids Topical corticosteroids are first-line for localized reactions like contact dermatitis. They suppress T cell activation and reduce cytokine production. Systemic corticosteroids are used for severe or widespread reactions. Calcineurin Inhibitors For severe or steroid-refractory cases, calcineurin inhibitors (such as tacrolimus or pimecrolimus) suppress T cell activation more specifically than corticosteroids and are especially useful when prolonged steroid use would cause unacceptable side effects. Antigen Avoidance The most effective management for contact dermatitis and drug-induced hypersensitivity is immediate cessation of the offending antigen or drug. Once the antigen is removed, the inflammatory response gradually resolves. Cytokine-Targeting Biologics <extrainfo> For chronic conditions with Type IV hypersensitivity components (like certain granulomatous diseases or severe contact dermatitis), disease-modifying biologic therapies targeting specific cytokines are sometimes used: Anti-IL-12/23 agents (ustekinumab) for granulomatous conditions TNF-α inhibitors for TB-associated granulomatous reactions IL-17 inhibitors for Type IVd-predominant conditions These represent newer therapeutic approaches in severe, refractory cases. </extrainfo> Supportive Care For drug-induced Type IV hypersensitivity reactions, supportive care—including antihistamines for itching, cool compresses, and emollients—helps manage symptoms while the immune response resolves. Key Takeaway: Type IV hypersensitivity is a T cell-mediated delayed reaction occurring 48-72 hours after antigen exposure. It has four distinct subtypes (IVa, IVb, IVc, IVd), each with different dominant cell types and cytokines. Recognizing which subtype is involved helps predict the clinical presentation, guide diagnosis, and select appropriate management. The hallmark diagnostic finding is delayed induration on skin testing, and histology shows immune infiltrates without antibody deposits.